Simplex Trading, LLC X4 Pharmaceuticals, Inc Transaction History

Simplex Trading, LLC

$2.81 Billion
Q3 2024

A detailed history of Simplex Trading, LLC transactions in X4 Pharmaceuticals, Inc stock. As of the latest transaction made, Simplex Trading, LLC holds 3,455 shares of XFOR stock, worth $1,174. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,455

Previous 75,405 95.42%

Holding current value

$1,174

Previous $43,000 95.35%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	SELL	$0.54 - $0.86 $38,853 - $61,877	-71,950 Reduced 95.42%	3,455 $2,000
Q2 2024 Jul 25, 2024	BUY	$0.58 - $1.47 $43,734 - $110,845	75,405 New	75,405 $43,000
Q4 2023 Feb 02, 2024	SELL	$0.61 - $0.99 $7,513 - $12,194	-12,318 Reduced 92.76%	962 $0
Q3 2023 Nov 01, 2023	SELL	$1.03 - $2.02 $219,684 - $430,837	-213,286 Reduced 94.14%	13,280 $14,000
Q2 2023 Aug 04, 2023	BUY	$0.82 - $2.49 $158,897 - $482,507	193,778 Added 591.0%	226,566 $439,000
Q1 2023 Apr 27, 2023	BUY	$0.8 - $1.22 $11,571 - $17,646	14,464 Added 78.93%	32,788 $28,000
Q4 2022 Feb 02, 2023	BUY	$0.69 - $2.21 $4,890 - $15,662	7,087 Added 63.07%	18,324 $18,000
Q3 2022 Nov 04, 2022	BUY	$0.89 - $1.71 $10,000 - $19,215	11,237 New	11,237 $19,000
Q2 2022 Aug 03, 2022	SELL	$0.88 - $1.91 $31,392 - $68,135	-35,673 Closed	0 $0
Q1 2022 May 02, 2022	BUY	$1.48 - $2.58 $44,938 - $78,339	30,364 Added 571.93%	35,673 $62,000
Q4 2021 Feb 23, 2022	BUY	$1.9 - $5.6 $9,986 - $29,433	5,256 Added 9916.98%	5,309 $12,000
Q2 2021 Aug 12, 2021	BUY	$6.49 - $9.56 $343 - $506	53 New	53 $0

Others Institutions Holding XFOR

# of Institutions

105

Shares Held

100M

Call Options Held

213K

Put Options Held

50.6K

View Full List

About X4 Pharmaceuticals, Inc

Ticker XFOR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,646,096
Market Cap $23.3M
Description
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...

More about XFOR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.

Account

Simplex Trading, LLC X4 Pharmaceuticals, Inc Transaction History